A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Journal of Bone and Mineral Research

Volumn 33, Issue 8, 2018, Pages 1383-1393

  Insogna, Karl L ^a   Briot, Karine ^b   Imel, Erik A ^c   Kamenický, Peter ^d   Ruppe, Mary D ^e   Portale, Anthony A ^f   Weber, Thomas ^g   Pitukcheewanont, Pisit ^h   Cheong, Hae Il ⁱ   Jan de Beur, Suzanne ^j   Imanishi, Yasuo ^k   Ito, Nobuaki ^l   Lachmann, Robin H ^m   Tanaka, Hiroyuki ⁿ   Perwad, Farzana ^f   Zhang, Lin ^o   Chen, Chao Yin ^o   Theodore Oklota, Christina ^o   Mealiffe, Matt ^o   San Martin, Javier ^o   Carpenter, Thomas O ^a   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Institut Cochin   (France)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ Seoul National University Children's Hospital   (South Korea)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^m UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁿ OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^o ULTRAGENYX PHARMACEUTICAL INC   (United States)

more..

Author keywords

BUROSUMAB; FGF23; OSTEOMALACIA; VITAMIN D; X LINKED HYPOPHOSPHATEMIA (XLH)

Indexed keywords

BUROSUMAB; PHOSPHATE; PLACEBO; BIOLOGICAL MARKER; CALCIUM; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MONOCLONAL ANTIBODY;

ADULT; AGED; AKATHISIA; ARTHRALGIA; ARTICLE; BACKACHE; BRIEF PAIN INVENTORY; CHRONIC PAIN; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTHESOPATHY; FEMALE; FORMICATION; FRACTURE; HEADACHE; HUMAN; HYPERPHOSPHATEMIA; HYPERSENSITIVITY; HYPOPHOSPHATEMIA; INJECTION SITE REACTION; KIDNEY CALCIFICATION; LIMB DEFORMITY; LIMB DISEASE; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MINERALIZATION; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; OROPHARYNX PAIN; OSTEOARTHRITIS; OSTEOMALACIA; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; RESTLESSNESS; RHINOPHARYNGITIS; RIGIDITY; SENSORY DYSFUNCTION; SHORT STATURE; SIDE EFFECT; TOOTH ABSCESS; UNSPECIFIED SIDE EFFECT; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; X LINKED HYPOPHOSPHATEMIC RICKETS; BONE REMODELING; CLINICAL TRIAL; DRUG EFFECT; FAMILIAL HYPOPHOSPHATEMIC RICKETS; HOMEOSTASIS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOMARKERS; BONE REMODELING; CALCIUM; DOUBLE-BLIND METHOD; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; MALE; PLACEBOS; TREATMENT OUTCOME;

EID: 85051290171     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.3475     Document Type: Article

References (25)

1. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11(2):130–6
2. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656–63
3. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637–47
4. Bonewald LF, Wacker MJ. FGF23 production by osteocytes. Pediatr Nephrol. 2013;28(4):563–8
5. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35
6. Shore RM, Chesney RW. Rickets: part I. Pediatr Radiol. 2013;43(2):140–51
7. Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13–30
8. Hardy DC, Murphy WA, Siegel BA, Reid IR, Whyte MP. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology. 1989;171(2):403–14
9. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore). 1989;68(6):336–52
10. Veilleux LN, Cheung M, Ben Amor M, Rauch F. Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J Clin Endocrinol Metab. 2012;97(8):E1492–8
11. Che H, Roux C, Etcheto A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325–33
12. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8
13. Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1992;75(3):879–85
14. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med. 1991;325(26):1843–8
15. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95(4):1846–50
16. Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587–97
17. Imel EA, Zhang X, Ruppe MD, et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab. 2015;100(7):2565–73
18. Ruppe M, Peacock M, Weber T, et al. Clinical and radiographic characteristics of adult X-linked hypophosphatemia (XLH) in a cohort of patients treated with KRN23, an antibody to FGF23. Presented at: ASBMR 2016 Annual Meeting, September 16–19, 2016; Atlanta, GA, USA. Presentation #MO0319
19. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17(2):197–210
20. Bellamy N. WOMAC osteoarthritis index user guide. Version X. Brisbane, Australia; 2012
21. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7
22. Pesta DH, Tsirigotis DN, Befroy DE, et al. Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB.J. 2016;30(10):3378–87
23. Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab. 1992;75(6):1514–8
24. Taylor A, Sherman NH, Norman ME. Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol. 1995;9(2):173–5
25. Carpenter TO, Insogna KL, Zhang JH, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010;95(11):E352–7